Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.140
+0.2101.24%
Volume:2.79M
Turnover:47.74M
Market Cap:45.47B
PE:11.54
High:17.260
Open:16.780
Low:16.780
Close:16.930
52wk High:28.232
52wk Low:14.505
Shares:2.65B
HK Float Shares:535.00M
Volume Ratio:0.49
T/O Rate:0.52%
Dividend:0.45
Dividend Rate:2.63%
EPS(LYR):1.486
ROE:6.95%
ROA:1.40%
PB:0.80
PE(LYR):11.54
PS:0.91

Loading ...

Fosun Pharma buys back 1.30 million H shares for HKD 22.24 million

Bulletin Express
·
Yesterday

Fosun Pharma Spends HK$22.24 Million to Buy Back 1.3 Million Shares

Stock News
·
Yesterday

AH Share Premium Rankings Update: September 16 Market Close

Stock News
·
Yesterday

Fosun Pharma Buys Back 1.30 Million H-Shares, Cutting Free Float by 0.24%

Bulletin Express
·
Sep 15

Fosun Pharma Spends HK$22.07 Million on Share Buyback on September 15

Stock News
·
Sep 15

Fosun Pharma Repurchases 1.46 Million H-Shares for HKD 24.71 Million; Treasury Stock Rises to 15.83 Million Units

Bulletin Express
·
Sep 14

Fosun Pharma Spends HK$24.7 Million Buying Back 1.455 Million Shares on September 14

Stock News
·
Sep 14

AH Share Premium Rankings as of September 14

Stock News
·
Sep 14

Chinese Drug Regulator Accepts Fosun Pharma's Application for HLX14; Shares Up 5%

MT Newswires Live
·
Sep 14

Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14

Stock News
·
Sep 11

Fosun Pharma Buys Back 1.34 Million H-Shares for HKD 21.86 Million, Raising Treasury Stock to 14.37 Million Shares

Bulletin Express
·
Sep 11

Fosun Pharma Spends Approximately HK$21.86 Million on Share Buyback

Stock News
·
Sep 11

Pharmaceutical Firms Divest Assets to Bolster Core Operations

Deep News
·
Sep 09

Fosun Pharma's New Oral Drug for Vitiligo Gets Green Light for Phase III Trials

Deep News
·
Sep 09

Fosun Pharma Repurchases 152,500 H-Shares for HK$2.63 Million on 9 September 2026

Bulletin Express
·
Sep 09

Fosun Pharma Spends HK$2.63 Million Buying Back Shares on September 9

Stock News
·
Sep 09

Sinopharm Group Stock Slips 2.1% in Hong Kong

Dow Jones
·
Sep 09

Fosun Pharma Receives NMPA Approval to Launch Phase II/III Trial for Dual JAK/TYK2 Inhibitor FXS5626 in Non-Segmental Vitiligo

Bulletin Express
·
Sep 08

Shanghai Fosun Pharma - Receives Nmpa Approval for Phase Ii/Iii Clinical Trial of Fxs5626

THOMSON REUTERS
·
Sep 08

Fosun Pharma's Subsidiary Obtains Regulatory Nod for FXS5626 Tablet Trial in Vitiligo Indication

Stock News
·
Sep 08